Delcath Systems Inc. (DCTH)
NASDAQ: DCTHHealth CareMedical/Dental InstrumentsUSD
Market open · Delayed 15 min · as of Oct 8, 12:00 PM ET
DCTH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $504.52M
- P/E (TTM)
- 1,454.00
- Forward P/E
- 323.11
- EPS (TTM)
- $0.01
- Dividend yield
- None
- 52-week range
- 8.12 – 17.42
- Day range
- 14.54 – 15.23
- Volume / Avg
- 137.26K / 478.44K
- Beta
- —
- Shares outstanding
- 34.70M
- Next earnings
- Nov 3, 2026
52-week range
DCTH stock today
Delcath Systems (DCTH) is trading at $14.54 on Oct 8, down 5.46% (-$0.84), versus the S&P 500's 0.40% decline. Shares are 16.5% below their 52-week high of $17.42, set on Aug 11, 2026 and 79.1% above the 52-week low of $8.12, in the middle of the past year's range. DCTH is up 52.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 42.4%.
At 1,454x trailing earnings, Delcath Systems's P/E ratio is unusually high because its trailing profit is very small relative to its share price. Delcath Systems's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Delcath Systems
Company profileDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Gerard J. Michel MBA, MS
- Headquarters
- Queensbury, NY
- Employees
- 156
- Website
- delcath.com
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$24.00+65.06%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.10
Delcath Systems peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SSIISS Innovations International Inc. | 2.70 | -1.45% | $540.00M | vs DCTH |
| KIDSOrthoPediatrics Corp. | 21.70 | -3.49% | $566.45M | vs DCTH |
| TCMDTactile Systems Technology Inc. | 21.93 | -0.43% | $496.65M | vs DCTH |
| SENSSenseonics Holdings Inc. | 8.99 | -1.86% | $475.34M | vs DCTH |
| ANGOAngioDynamics Inc. | 11.15 | -21.42% | $468.91M | vs DCTH |
| BWAYBrainsWay Ltd. ADR | 11.53 | -0.78% | $464.11M | vs DCTH |
| SGHTSight Sciences Inc. | 8.12 | -4.13% | $447.31M | vs DCTH |
| CERSCerus Corporation | 2.21 | -3.72% | $444.36M | vs DCTH |
Indexes, lists and sector
Delcath Systems stock FAQ
What is Delcath Systems's stock price today?
DCTH last traded at $14.54 as of Oct 8, 12:00 PM EDT, down 5.46% on the day. Prices are delayed at least 15 minutes.
Does Delcath Systems pay a dividend?
No. Delcath Systems does not currently pay a regular cash dividend.
When is Delcath Systems's next earnings date?
Delcath Systems is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.10.
What is DCTH's P/E ratio?
DCTH trades at a trailing P/E ratio of 1454.00 and a forward P/E of 323.11.
Who is Delcath Systems's CEO?
Mr. Gerard J. Michel MBA, MS is the chief executive officer of Delcath Systems Inc., which has about 156 employees.
Has DCTH ever split its stock?
Yes. The most recent DCTH stock split was a 1-for-700 split on Dec 24, 2019.
What is the DCTH 52-week high?
The 52-week high for DCTH is $17.42 and the 52-week low is $8.12. The stock is currently 16.5% below its high.